RTW Foundation donates $8 million to reimagine physician training in Penn’s Perelman School of Medicine
News

RTW Foundation donates $8 million to reimagine physician training in Penn’s Perelman School of Medicine

Published

January 22, 2026, Philadelphia, PA – A landmark $8 million gift from the RTW Foundation, led by Penn Medicine Board of Trustees member Rod Wong, M’03, and Marti Speranza Wong, C’98, will launch a bold initiative to reimagine medical education at the Perelman School of Medicine at the University of Pennsylvania. It is the single largest donation to support curriculum innovation in PSOM history, ensuring that the nation’s first medical school will continue to lead in training physicians for generations to come.

The project will bring together faculty, staff, and students to create and implement a new curriculum built for the future of medicine: an era when gene therapies have reshaped the promise of cures for an array of diseases, artificial intelligence is putting new treatments closer at hand than ever, and the rise of remote monitoring and telemedicine are changing the ways in which doctors interact with patients.

The new curriculum will integrate technology, AI, and data in powerful ways, providing greater flexibility and customized learning plans to students through the concept of precision education, a methodology inspired by precision medicine, which personalizes treatments for patients based on genetics, environment, and lifestyle. Emerging tools like ambient listening technology, for instance, will help students develop clinical reasoning skills and work in teams with other types of health care professionals. Customized AR/VR simulations will help students to better understand anatomy, master crucial knowledge to diagnose illness and develop treatment plans, and enhance training for procedural skills such as ultrasounds and suturing. By building a vast ecosystem of data and interwoven AI tools – such as insights drawn from how students use Penn’s electronic medical record (EMR) system during clinical education – each of the school’s nearly 800 student doctors will have a more personalized pathway to guide their education.

Together, these elements will support training flexibility and innovation as the field races ahead. Those same qualities have also guided Rod Wong’s entrepreneurial success and vision through a professional journey spanning medicine, business, and biotech investment.

“I see interdisciplinary work in motion all across Penn, and it’s powerful when students and faculty have the runway to expand their thinking. This gift from the RTW Foundation, powering a leading approach to medical education with an entrepreneurial model will be another groundbreaking way that the Perelman School of Medicine is the setting the standard for the future of medicine,” said J. Larry Jameson, MD, PhD, President of the University of Pennsylvania. “Rod and Marti exemplify the very best of Penn—visionary alumni leaders whose commitment to advancing medicine will shape generations to come.”

Why Penn, why now

"I believe medical innovation is the key to life being better in the future than it is today" Wong said. "And as science accelerates, to train physicians for the future, so should education. Penn has the courage and the team to pursue this, which is why I am so excited to have the opportunity to support this effort."

Wong and the RTW Foundation have a history of encouraging “out of the box” thinking at the Perelman School of Medicine. In 2013, PSOM created the innovative, student-led PennHealthX with Wong’s support – a program which encourages students to explore their interests at the intersection of health care management, entrepreneurship, and technology. Among other activities, the program has funded more than 50 student-run startups in areas ranging from allergen detection in food to top-rated medicine reminder apps to AI caregiving companions.

The new gift will also allow PSOM to host the Roderick Wong, M’03 Endowed Lectureship in business and entrepreneurship twice each year, which will bring leaders in medicine and health care innovation to campus. In addition, it will establish the Roderick Wong Entrepreneurship Pathway, designed to provide mentorship, workshops, and project-based learning to support bold thinking. The model builds on Penn’s longstanding tradition of empowering students to incorporate passions and interests that draw on the University’s 12 schools.

“I’ve been at Penn for 30 years, and I’m so proud of the doctors who’ve trained here, whether they have pursued clinical care, research, entrepreneurship, or other paths. But much has changed in that time, both in the information we must teach and in the ways students can learn best,” said Jonathan A. Epstein, MD, Dean of the Perelman School of Medicine and Executive Vice President of the University of Pennsylvania for the Health System. “This generous gift empowers us to experiment with cutting-edge teaching methods and tools to build a curriculum that keeps pace as medicine continues to evolve.”

Setting a new standard for medical education

Historically, medical student education has been structured as a one-size-fits-all approach with lecture and small-group courses covering all the body’s systems, labs, and clinical rotations to get real-world patient care experience. The PSOM curriculum reimagination is a new chapter that began with “Curriculum 2000” under the leadership of longtime PSOM Senior Vice Dean for Education Gail Morrison, MD, who introduced training in the late 1990s that emphasized professionalism, patient-centered care, and humanism. Curriculum 2000 also saw the creation of a robust “standardized patient” program using medical actors that continues to be an essential part of PSOM training. The new effort will be led by Lisa M. Bellini, MD, Executive Vice Dean of the Perelman School of Medicine and Senior Vice President for Academic Affairs for the University of Pennsylvania Health System, and Jennifer R. Kogan, MD, Vice Dean for Undergraduate Medical Education—both internationally recognized leaders in medical education and faculty development who have built their careers at Penn Medicine.

Conducting research and testing the new approaches will be a key focus, as well. By sharing new tools in an open-source format for other schools to use, the reimagined curriculum has the potential to influence medical education around the world, building on Penn Medicine’s partnerships with VinUniversity in Vietnam, where leaders helped establish the country's first private not-for-profit medical school, and the American University in Dubai, where the UAE’s premier medical school will open in 2027.

“Training the next generation of physicians who will shape and advance medicine requires weaving new technologies into education while helping students understand both community needs and the power of highly personalized care,” Kogan said. “We are building on Penn’s legacy of leading in education to create a more flexible, personalized journey that fuels curiosity, supports student well-being, and prepares them to give every patient the very best care.”

About Penn Medicine 
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System (UPHS) and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $580 million awarded in the 2023 fiscal year. Home to a proud history of “firsts,” Penn Medicine teams have pioneered discoveries that have shaped modern medicine, including CAR T cell therapy for cancer and the Nobel Prize-winning mRNA technology used in COVID-19 vaccines.

The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital,

Doylestown Health, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.9 billion enterprise powered by more than 50,000 talented faculty and staff.

About RTW Foundation
Founded in 2018 as the philanthropic arm of RTW Investments, LP, RTW Foundation works to power community initiatives and provide rare disease advising to improve the health of underserved populations. The Foundation supports the development of medicines for neglected rare diseases, empowers youth to explore careers in science, biotechnology, and medicine, and builds partnerships with local organizations to advance health equity in New York City. To learn more, visit www.rtwf.org

This website is not intended to offer or to promote the offer or sale of the shares (the “Shares”) of RTW Biotech Opportunities Ltd (the “Company”) in the United States or to any “U.S. persons” as defined in Regulation S (“US persons”) under the US Securities Act of 1933, as amended (the “Securities Act”). The materials contained herein are not for release, publication or distribution, directly or indirectly, in whole or in part, to any persons to whom or into or within any jurisdiction where to do so would constitute a violation of applicable law or regulation.

The information contained herein and on the pages that follow does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which, or to any person to whom, such an offer or solicitation would be unlawful.

The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the “Investment Company Act”), and as such holders of the Shares are not and will not be entitled to the benefits of the Investment Company Act. The Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, assigned or otherwise transferred, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not result in the Company being required to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. The offer and sale of the Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan or South Africa. Potential users of the information contained herein and on the pages that follow are requested to inform themselves about and to observe all applicable restrictions.

The information contained herein and on the pages that follow may contain forward-looking statements. Any statement other than a statement of historical fact is a forward-looking statement. Actual results may differ materially from those expressed or implied by any forward-looking statement. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. You should not place undue reliance on any forward-looking statement, which speaks only as of the date of its issuance. The Company may change these terms and conditions from time to time and any such changes will be posted on this website. Your access to this website is governed by the version of these terms and conditions then in force.

By clicking “Agree” below, you represent, warrant, undertake and agree that (1) you have read, understood and agree to be bound by the terms and conditions and other information set out herein, (2) you are permitted under applicable laws and regulations to receive the information contained herein and on the pages that follow, (3) you are either (a) located outside the United States and are not a US Person or (b) an existing shareholder of the Company who is a “qualified purchaser” as defined under the Investment Company Act and (4) you will not further transmit or send any information contained in this website to any other persons in the United States, to US Persons, or to any publications with a general circulation in the United States. If you cannot so represent, warrant, undertake and agree, you must click the button labelled “Decline” or otherwise exit this website.